CS
EIGR

Candriam SCA’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Candriam SCA’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-411
Closed -$3.5M – 667
2015
Q1 		$3.5M Buy
411
+55
+15% +$481K 0.07% 310
2014
Q4 		$3.13M Buy
+356
New +$2.07M 0.07% 301

Other funds holding EIGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Candriam SCA's EIGR Position: Q2 2015 in Review

Candriam SCA sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2015, closing a stake of 411 shares — an estimated $3.5M sold.

Candriam SCA first reported a position in EIGR in Q4 2014 and held it in 2 quarters. The position peaked at $3.5M in Q1 2015. 44 funds tracked by Wall St. Rank hold EIGR as of Q2 2015.

  • Candriam SCA reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Candriam SCA sold 411 Eiger BioPharmaceuticals, Inc. shares in Q2 2015, an estimated $3.5M.
  • Candriam SCA first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
  • Candriam SCA's Eiger BioPharmaceuticals, Inc. position peaked at $3.5M in Q1 2015.
  • 44 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2015.

Based on Candriam SCA's 13F filing for Q2 2015, filed 29 Jul 2015.